TrialThe Lancet. Oncology2019

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

Stephanie M de Boer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.